Importance of exercise in the control of metabolic and inflammatory parameters at the moment of onset in type 1 diabetic subjects

Experimental and Clinical Endocrinology and Diabetes

Volumn 122, Issue 6, 2014, Pages 334-340

  Martinez Ramonde T ^a   Alonso, N ^b   Cordido, F ^a   Cervello E ^b   Canizares A ^a   Martinez Peinado P ^c   Sempere, J M ^c   Roche, E ^b,d  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c UNIVERSITY OF ALICANTE   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

C peptide; glycated haemoglobin; inflammation; cell mass

Indexed keywords

ALPHA INTERFERON; C PEPTIDE; CARBONYL DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; EXERCISE; FEMALE; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLIC PARAMETERS; METABOLIC REGULATION; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SEDENTARY LIFESTYLE; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; FOLLOW UP; KINESIOTHERAPY; METABOLISM; ONSET AGE; PILOT STUDY; TIME;

AGE OF ONSET; C-PEPTIDE; CYTOKINES; DIABETES MELLITUS, TYPE 1; EXERCISE THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; MALE; PILOT PROJECTS; TIME FACTORS;

EID: 84902830125     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1372581     Document Type: Article

References (38)

1. Boitard C. Pancreatic islet autoimmunity. Presse Med: 2012; 41 e636 e650
2. Notkins A. L. Immunologic and genetic factors in type 1 diabetes. J Biol Chem: 2002; 277 43545 43548 (Pubitemid 36157765)
3. Rabinovitch A., Suarez-Pinzon W. L. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rev Endocr Metab Disord: 2003; 4 291 299 (Pubitemid 37082202)
4. Nathan D. M., Zinman B., Cleary P. A. et al. DCCT/EDIC Groups. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med: 2009; 169 1307 1316
5. Gupta S. Immunotherapies in diabetes mellitus type 1. Med Clin North Am: 2012; 96 621 634
6. Ludvigsson J. Novel therapies in the management of type I diabetes mellitus. Panminerva Med: 2012; 54 257 270
7. Gallagher M. P., Goland R. S., Greenbaum C. J. Making progress: preserving beta cells in type 1 diabetes. Ann N Y Acad Sci: 2011; 1243 119 134
8. Sethi G., Sung B., Kunnumakkara A. B. et al. for Treatment of Cancer and Autoimmunity. Adv Exp Med Biol: 2009; 647 37 51
9. Nielsen P. J., Hafdahl A. R., Conn V. S. et al. Meta-analysis of the effect of exercise interventions on fitness outcomes among adults with type 1 and type 2 diabetes. Diabetes Res Clin Pract: 2006; 74 111 120 (Pubitemid 44764908)
10. Conn V. S., Hafdahl A. R., Lemaster J. W. et al. Meta-analysis of health behavior change interventions in type 1 diabetes. Am J Health Behav: 2008; 32 315 329
11. Jakicic J. M., Clark K., Coleman E. et al. American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc: 2001; 33 2145 2156 (Pubitemid 33126711)
12. Levine R. L., Williams J. A., Stadtman E. R. et al. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol: 1994; 233 346 357
13. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes Diabetes Care: 2009; 32 1327 1334
14. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care: 2010; 33 01 S62 S69
15. Ali M. A., Dayan C. M. The importance of residual endogenous beta-cell preservation in type 1 diabetes. Br J Diab Vasc Dis: 2009; 9 248 253
16. Mortensen H. B., Hougaard P., Swift P. et al. Hvidoere Study Group on Childhood Diabetes. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care: 2009; 32 1384 1390
17. Robertson R. P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem: 2004; 279 42351 42354
18. van Belle T. L., Coppieters K. T., von Herrath M. G. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev: 2011; 91 79 118
19. Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab Res Rev: 2009; 25 307 315
20. Baumann B., Salem H. H., Boehm B. O. Anti-inflammatory therapy in type 1 diabetes. Curr Diab Rep: 2012; 12 499 509
21. Fredheim S., Johansen J., Johansen A. et al. Danish Society for Diabetes in Childhood and Adolescence. Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia: 2013; 56 995 1003
22. Niess A. M., Simon P. Response and adaptation of skeletal muscle to exercise - the role of reactive oxygen species. Front Biosci: 2007; 12 4826 4838
23. Hirose L., Nosaka K., Newton M. et al. Changes in inflammatory mediators following eccentric exercise of the elbow flexors. Exerc Immunol Rev: 2004; 10 75 90
24. Malm C. Exercise immunology: the current state of man and mouse. Sports Med: 2004; 34 555 566 (Pubitemid 39159006)
25. Toft A. D., Jensen L. B., Bruunsgaard H. et al. Cytokine response to eccentric exercise in young and elderly humans. Am J Physiol Cell Physiol: 2002; 283 C289 C295 (Pubitemid 34670573)
26. Singh B., Nikoopour E., Huszarik K. et al. Immunomodulation and regeneration of islet beta cells by cytokines and autoimmune type 1 diabetes. J Interf Cytok Res: 2011; 31 711 719
27. Yamanouchi J., Rainbow D., Serra P. et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet: 2007; 39 329 337 (Pubitemid 46328484)
28. Sgouroudis E., Albanese A., Piccirillo C. A. Impact of protective IL-2 allelic variants on CD4+Foxp3+regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J Immunol: 2008; 181 6283 6292
29. Grinberg-Bleyer Y., Baeyens A., You S. et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med: 2010; 207 1871 1878
30. Tang Q., Adams J. Y., Penaranda C. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity: 2008; 28 687 697
31. Rapoport M. J., Jaramillo A., Zipris D. et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med: 1993; 178 87 99 (Pubitemid 23173245)
32. Goudy K. S., Burkhardt B. R., Wasserfall C. et al. Systemic overexpression of IL-10 induces CD4+CD25+cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol: 2003; 171 2270 2278 (Pubitemid 37025531)
33. Hillhouse E. E., Beauchamp C., Chabot-Roy G. et al. Interleukin-10 limits the expansion of immunoregulatory CD4-CD8- T cells in autoimmune-prone non-obese diabetic mice. Immunol Cell Biol: 2010; 88 771 780
34. Xiong X., Wang X., Li B. et al. Pancreatic islet-specific overexpression of Reg3β protein induced the expression of pro-islet genes and protected the mice against streptozotocin-induced diabetes mellitus. Am J Physiol Endocrinol Metab: 2011; 300 E669 E680
35. Vicente-Salar N., Santana A., Reig J. et al. Differentiation of embryonic stem cells using pancreatic bud-conditioned medium gives rise to neuroectoderm-derived insulin-secreting cells. Cell Reprogram: 2011; 13 77 84
36. Shioya M., Andoh A., Kakinoki S. et al. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas: 2008; 36 197 199
37. Rosa J. S., Oliver S. R., Mitsuhashi M. et al. Altered kinetics of interleukin-6 and other inflammatory mediators during exercise in children with type 1 diabetes. J Investig Med: 2008; 56 701 713
38. Luo C., Li B., Yin H. P. et al. Transcriptional activation of Reg2 and Reg3β genes by glucocorticoids and interleukin-6 in pancreatic acinar and islet cells. Mol Cell Endocrinol: 2012; 365 187 196